# A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma

> **NCT06019637** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (estimated)

## Conditions studied

- Spinal Muscular Atrophies

## Interventions

- **OTHER:** Onasemnogene Abeparvovec

## Key facts

- **NCT ID:** NCT06019637
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-22
- **Primary completion:** 2038-09-30
- **Final completion:** 2038-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06019637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06019637, "A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06019637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*